Literature DB >> 19902312

Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus.

Joyce Wong1, Allison Schulman, Kaitlyn Kelly, Dmitriy Zamarin, Peter Palese, Yuman Fong.   

Abstract

INTRODUCTION: Cytologic detection of peritoneal gastric cancer cells by Papanicolaou staining offers important prognostic information but has low sensitivity. We evaluated a novel detection technique using Newcastle disease virus expressing the enhanced green fluorescent protein (NDV-GFP) gene.
METHODS: NDV-GFP was tested on MKN-1 human gastric adenocarcinoma cells plated upon rat hepatocytes to determine tumor-specific infection and GFP expression. Malignant ascites infected with increasing doses of virus was evaluated for NDV-GFP dose determination. Peritoneal lavage samples from 30 patients with gastric adenocarcinoma undergoing staging laparoscopy were evaluated with NDV-GFP.
RESULTS: NDV-GFP can specifically detect one MKN-1 cell among one million benign rat hepatocytes. NDV-GFP at 5 x 10(6) plaque-forming units (PFU) produced optimal GFP expression in malignant ascites. Noncancerous cells were non-GFP expressing. GFP-expressing cells counterstained positive for carcinoembryonic antigen expression, confirming their cancerous origin. Furthermore, in patients with advanced gastric cancer, GFP expression was markedly enhanced over cytology. Of six patients with M1 disease discovered during laparoscopy, only 50% were cytology positive. All six, however, were NDV-GFP positive. Cytology was positive in 9% of patients with T3 disease, 8% with N1 disease, and 50% with N2 disease. In contrast, NDV-GFP was positive in 95% of T3 patients and 100% of patients with N1 or N2 disease.
CONCLUSIONS: NDV-GFP can specifically infect and detect peritoneal gastric cancer cells and offers a more sensitive method compared with conventional cytology. This novel modality may offer enhanced detection of intraperitoneal cancer spread and provide important prognostic information.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19902312      PMCID: PMC3269812          DOI: 10.1007/s11605-009-1071-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  18 in total

Review 1.  Viral oncolysis.

Authors:  John T Mullen; Kenneth K Tanabe
Journal:  Oncologist       Date:  2002

Review 2.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

3.  Recombinant Newcastle disease virus as a vaccine vector.

Authors:  T Nakaya; J Cros; M S Park; Y Nakaya; H Zheng; A Sagrera; E Villar; A García-Sastre; P Palese
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Generation of recombinant lentogenic Newcastle disease virus from cDNA.

Authors:  Angela Römer-Oberdörfer; Egbert Mundt; Teshome Mebatsion; Ursula J Buchholz; Thomas C Mettenleiter
Journal:  J Gen Virol       Date:  1999-11       Impact factor: 3.891

5.  Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.

Authors:  Andrew L Pecora; Naiyer Rizvi; Gary I Cohen; Neal J Meropol; Daniel Sterman; John L Marshall; Stuart Goldberg; Peter Gross; James D O'Neil; William S Groene; M Scot Roberts; Harvey Rabin; Michael K Bamat; Robert M Lorence
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

6.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

Review 7.  Current treatments and future perspectives in colorectal and gastric cancer.

Authors:  H-J Wilke; E Van Cutsem
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

8.  Expression of transgenes from newcastle disease virus with a segmented genome.

Authors:  Qinshan Gao; Man-Seong Park; Peter Palese
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

9.  Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer.

Authors:  G Blackshaw; W G Lewis; A N Hopper; M A Morgan; W Al-Khyatt; P Edwards; S A Roberts
Journal:  Clin Radiol       Date:  2008-08-09       Impact factor: 2.350

10.  Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?

Authors:  Brian Badgwell; Janice N Cormier; Sunil Krishnan; James Yao; Gregg A Staerkel; Philip J Lupo; Peter W T Pisters; Barry Feig; Paul Mansfield
Journal:  Ann Surg Oncol       Date:  2008-07-23       Impact factor: 5.344

View more
  4 in total

1.  PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

Authors:  Dmitriy Zamarin; Jacob M Ricca; Svetlana Sadekova; Anton Oseledchyk; Ying Yu; Wendy M Blumenschein; Jerelyn Wong; Mathieu Gigoux; Taha Merghoub; Jedd D Wolchok
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

Review 2.  Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients.

Authors:  Shunsuke Kagawa; Kunitoshi Shigeyasu; Michihiro Ishida; Megumi Watanabe; Hiroshi Tazawa; Takeshi Nagasaka; Yasuhiro Shirakawa; Toshiyoshi Fujiwara
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

3.  Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.

Authors:  Mena Mansour; Peter Palese; Dmitriy Zamarin
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

Review 4.  Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy.

Authors:  Fang Huang; Chuanjing Dai; Youni Zhang; Yuqi Zhao; Yigang Wang; Guoqing Ru
Journal:  Front Mol Biosci       Date:  2022-07-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.